Jagan Beedupalli, MD
Cardiovascular Disease · Shreveport, LANPI 1497956601
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Boston Scientific at 34.9% of the total.
Across 335 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Penumbra, Inc.$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Itamar Medical Inc$803
- Abiomed$644
- Medtronic$562
- plus $3K from 30 others
What the payments were for
- Travel & lodging$5,42341%
- Food & beverage$7,58358%
- Entertainment$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 70 | $4,566 |
| Penumbra, Inc. | 7 | $2,624 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 77 | $1,056 |
| Itamar Medical Inc | 6 | $803 |
| Abiomed | 24 | $644 |
| Medtronic(2 entities) | 10 | $562 |
| Shockwave Medical, Inc | 17 | $315 |
| Inari Medical, Inc. | 15 | $236 |
| Philips North America LLC | 5 | $222 |
| Irhythm Technologies, Inc. | 11 | $218 |
| E.r. Squibb & Sons, L.L.C. | 11 | $204 |
| Stryker | 11 | $193 |
| Pfizer | 9 | $134 |
| Novartis | 8 | $128 |
| Amgen | 8 | $122 |
| Merck | 7 | $112 |
| Bayer | 6 | $110 |
| Endologix LLC | 1 | $109 |
| Johnson & Johnson | 6 | $101 |
| Terumo Medical Corporation | 1 | $100 |
| Cardiovascular Systems Inc. | 1 | $83 |
| Atricure, Inc. | 1 | $67 |
| AstraZeneca | 4 | $57 |
| Novo Nordisk | 3 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 3 | $41 |
| Contego Medical, Inc | 2 | $24 |
| Abbott | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Preventice Services, LLC | 1 | $19 |
| ZOLL Circulation Inc | 1 | $18 |
| GSK | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Recor Medical Inc | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Cvrx, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$2,560
- Indigo System$2,343
- ANGIOJET$707
- WatchPat$391
- WatchPATONE$293
- Endurant$225
- Penumbra System$146
- Impella$135
- ELUVIA$123
- IGT D Peripheral$121
- Smart Coil$110
- Alto Abdominal Stent Graft System$109
- METACROSS OTW$100
How this compares
$13,086 in reported general payments places this provider in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 208 | $157,322 |
| EliquisApixaban | 205 | $150,611 |
| JardianceEmpagliflozin | 172 | $126,846 |
| BrilintaTicagrelor | 78 | $41,864 |
| Repatha SureclickEvolocumab | 32 | $27,070 |
| XareltoRivaroxaban | 26 | $25,999 |
| FarxigaDapagliflozin Propanediol | 22 | $16,938 |
| Metoprolol Succinate | 332 | $3,322 |
| Propafenone Hcl ErPropafenone Hcl | 13 | $2,754 |
| Rosuvastatin Calcium | 103 | $2,528 |
| Atorvastatin Calcium | 366 | $2,240 |
| Ezetimibe | 145 | $1,990 |
| ClopidogrelClopidogrel Bisulfate | 200 | $1,793 |
| Nifedipine ErNifedipine | 57 | $1,480 |
| Amiodarone Hcl | 50 | $1,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $128 | $157,322208 claims |
| PfizerEliquis | $134 | $150,611205 claims |
| Boehringer IngelheimJardiance | $17 | $126,846172 claims |
| AstraZenecaBrilinta, Farxiga | $57 | $58,801100 claims |
| Johnson & JohnsonXarelto | $101 | $25,99926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Shreveport
- Basel KasabaliShreveport$30K
- Tina FirouzbakhtShreveport$28K
- Wenwu ZhangShreveport$21K
- William EavesShreveport$15K
- Mahin KhanShreveport$10K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.